Literature DB >> 33543653

Impact of Body Mass Index on Survival Outcome in Patients with Newly Diagnosed Glioblastoma: A Retrospective Single-Center Study.

Jun-Yong Cha1, Jae-Sung Park1, Yong-Kil Hong1, Sin-Soo Jeun1, Stephen Ahn1.   

Abstract

INTRODUCTION: The impact of obesity on survival outcomes in patients with glioblastoma (GBM) has not been well reported and the results for patients are currently unclear. We investigated the effect of obesity on survival outcomes in patients with newly diagnosed GBM.
METHODS: Using electronic medical records, all GBM patients that visited the Seoul St. Mary's Hospital between 2008 and 2018 were reviewed. A total of 177 patients met our eligibility criteria. The cut-off point for BMI was 23.0 kg/m2 based on previous studies which focused on Asian populations.
RESULTS: A total of 177 patients met our eligibility criteria. The overall median BMI of patients was 24.5 kg/m2 (range 15.82-39.26). About 62 patients who had a BMI less than the cut-off value were assigned to the "lower BMI" group, while 115 patients who had a BMI greater than the cut-off value were assigned to the "higher BMI" group. In Kaplan-Meier survival analysis, the median OS of the higher BMI group was longer than that of the lower BMI group (21.3 months vs 15.3 months, P = .002). In multivariate Cox regression analysis for OS, lower BMI was associated with inferior OS (HR 1.48 CI 1.06-2.08, P = .002).
CONCLUSION: Our findings suggest that elevated BMI may be associated with better survival in patients with newly diagnosed GBM. Additional larger prospective studies could help validate our findings to confirm the effect of body composition and survival outcomes in GBM patients.

Entities:  

Keywords:  body mass index; cancer; glioblastoma; obesity; survival

Year:  2021        PMID: 33543653     DOI: 10.1177/1534735421991233

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  2 in total

1.  Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma.

Authors:  Stephen Ahn; Young Il Kim; Ja Young Shin; Jae-Sung Park; Changyoung Yoo; Youn Soo Lee; Yong-Kil Hong; Sin-Soo Jeun; Seung Ho Yang
Journal:  Oncol Lett       Date:  2022-02-09       Impact factor: 2.967

2.  Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.

Authors:  Johannes Weller; Niklas Schäfer; Christina Schaub; Anna-Laura Potthoff; Joachim P Steinbach; Uwe Schlegel; Michael Sabel; Peter Hau; Clemens Seidel; Dietmar Krex; Roland Goldbrunner; Torsten Pietsch; Theophilos Tzaridis; Thomas Zeyen; Valeri Borger; Erdem Güresir; Hartmut Vatter; Ulrich Herrlinger; Matthias Schneider
Journal:  J Neurooncol       Date:  2022-06-15       Impact factor: 4.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.